This article is more than 5 years old. Information may no longer be current.

10 updates in immunotherapy research

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

In recognition of Cancer Immunotherapy Month, Cancer Research Institute has organized a series of educational and social events designed to raise awareness regarding these treatment options.

In conjunction with their efforts, HemOnc Today presents 10 updates in immunotherapy treatment and research that may affect your practice.

• Nivolumab (Opdivo, Bristol-Myers Squibb) — a PD-1 inhibitor — did not result in longer PFS than platinum-based chemotherapy as first-line treatment for stage IV or recurrent non–small cell lung cancer in patients with a PD-L1 expression level of 5% or more. However, it did confer higher response rates in patients with PD-L1 expression level of 50% or more and high tumor mutational burden. Read more.
• The use of sipuleucel-T (Provenge, Dendreon) in patients with hormone-sensitive and castration-resistant prostate cancer demonstrated an increase in the proliferation of CD4 and CD8 T cells at week 6 compared with baseline. Watch here.
• Three companies — eFFECTOR Therapeutics, Pfizer and Merck KGaA — entered a clinical collaboration to evaluate the combination of eFT508 (eFFECTOR Therapeutics) and avelumab (Bavencio, EMD Serono) for patients with microsatellite stable colorectal cancer. Read more.
• The addition of cetuximab (Erbitux, Eli Lilly), an EGFR inhibitor, or bevacizumab (Avastin, Genentech), a humanized murine antihuman VEGF monoclonal antibody, to a first-line chemotherapy regimen demonstrated similar OS, PFS and response rates in patients with KRAS wild-type untreated advanced or metastatic colorectal cancer. Read more.
• Jarushka Naidoo, MBBCh, spoke with HemOnc Today at the ASCO Annual Meeting about the Institute for Clinical Immuno-Oncology — an initiative of the Association of Community Cancer Centers designed to allow experts from academic facilities to share their expertise in cancer immunotherapies directly with community providers. Watch here.
• Nivolumab alone or in combination with ipilimumab (Yervoy, Bristol-Myers Squibb) demonstrated encouraging activity in patients with relapsed malignant pleural mesothelioma, according to results of the randomized, phase 2 IFCT-1501 MAPS2 trial. Read more.
• Pembrolizumab (Keytruda, Merck) improved survival in patients with NSCLC who previously underwent radiation therapy. Read more.
• Andrew B. Lassman , MD, discusses advances made within two major themes — precision medicine and immunotherapy — for the treatment of primary brain tumors. Watch here.
• Nivolumab plus ipilimumab led to durable responses in previously treated patients with small cell lung cancer, according to results from the CheckMate 032 trial. Read more.
• PAGE BREAK
• Jeremy Slade Abramson, MD, clinical director of the Center for Lymphoma at Massachusetts General Hospital Cancer Center, provided perspective on the phase 3b MAGNIFY trial presented at the ASCO Annual Meeting, which showed promise for the combination of lenalidomide (Revlimid, Celgene) and rituximab (Rituxan; Genentech, Biogen) for follicular lymphoma. Watch here.